144
Participants
Start Date
May 7, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
December 30, 2026
AMT-116
AMT-116 is an antibody Drug Conjugate (ADC)
RECRUITING
Fujian Cancer Hospital, Fuzhou
NOT_YET_RECRUITING
Dongguan People's Hospital, Dongguan
RECRUITING
Zhujiang Hospital of Southern Medical University(The Second Clinical Medical College), Guangzhou
RECRUITING
Guangxi Medical University Cancer Hospital, Nanning
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Zhejiang cancer hospital, Hangzhou
RECRUITING
The Second Affiliated Hospital and Yuying Childrens Hospital of Wenzhou Medical University, Wenzhou
Lead Sponsor
Multitude Therapeutics Inc.
INDUSTRY